

Variable Outcomes After Metabolic Surgery: *Science or Selection?*

Ali Aminian, MD, FACS, FASMBS

Professor of Surgery

Director, Bariatric and Metabolic Institute



Cleveland Clinic
Bariatric and Metabolic Institute



Disclosures

- Amgen (research grant)
- Amylyx (consulting)
- Eli Lilly (member of steering committee of a clinical trial)
- Ethicon (research grant, consulting)
- iRhythm (research grant)
- Medtronic (research grant, consulting)
- NIH (research grant)

“Individual” Response

Always

Varies

With Any Therapy

Response Varies All the Time

➤ Cancer response to chemotherapy

❖ Cure vs Death

Response Varies All the Time


- **Cancer response to chemotherapy**

- ❖ Cure vs Death



- **Lupus response to anti-inflammatory drugs**

- ❖ Remission vs Progression

Once-Weekly Semaglutide in Adolescents with Obesity



Once-Weekly Semaglutide in Adolescents with Obesity




Gained 10%


Lost 50%

ORIGINAL ARTICLE


Weight and Metabolic Outcomes 12 Years after Gastric Bypass




ORIGINAL ARTICLE

Weight and Metabolic Outcomes 12 Years
after Gastric Bypass


Individual Response to RYGB and SG



Individual
Response
to RYGB
and SG



Individual
Response
to RYGB
and SG



Why Variable Outcomes?

Whatever Dr Cummings Just

Explained Applies Here Too



Selection Explains Some

Behavior Explains Some

Biology Explains More

Multiple Mechanisms of Action Support Longterm Effect of Bariatric Surgery

Response is heterogeneous, not always sustained



Variable Outcomes After Metabolic Surgery

Multifactorial



1. ANATOMICAL

- Poorly constructed anatomy
- Pouch dilation
- Enlarged GJ anastomosis
- Gastro-gastric fistula
- Dilated sleeve



2. BEHAVIORAL

- Unhealthy diet pattern
- Loss-of-control eating
- Grazing
- Low physical activity
- Alcohol use / abuse



3. PSYCHOSOCIAL & CARE-RELATED

- Depression / anxiety
- Non-adherence
- Lack of follow-up
- Limited support
- Social determinants / environment



4. MEDICAL / PHARMACOLOGIC

- Weight gain-promoting medications
- Endocrine disorders
- Sleep deprivation
- Smoking cessation
- New medical comorbidities



5. RESISTANT BIOLOGY

- Adaptive thermogenesis
- Persistent hunger / hyperphagia
- Reduced satiety signaling
- Energy expenditure adaptation
- Neurohormonal compensation



6. GENETIC / GENOMIC FACTORS

- Polygenic susceptibility
- MC4R pathway variants
- Appetite / satiety pathway variants
- Reward pathway differences
- Pharmacogenomic variability



Outcomes after metabolic surgery result from a complex interplay of anatomical, behavioral, medical, biological, genetic, and psychosocial factors. A **comprehensive, personalized approach** is essential for long-term success.

Check for Weight Gain Promoting Medications


Depression Tricyclics eg. trazodone, nortriptyline, amitriptyline SSRIs eg paroxetine, citalopram, escitalopram Others eg mirtazipine, venlafaxine	Diabetes Insulin Sulfonylureas eg glipizide Thiazolidinediones eg pioglitazone
Atypical antipsychotics Clozapine, olanzapine, quetiapine, risperidone, aripiprazole	Hypertenion Betablockers, Propranolol, metoprolol, atenolol
Seizures Gabapentin, valproic acid	Allergy Diphenhydramine, hydroxyzine, cetirizine, fexofenadine
Miscellaneous Lithium	Glucocorticoids Prednisone, methylprednisone
Other Tamoxifen, HAART	Contraception Depoprovera

Preoperative Predictors: Useful, but Incomplete

- Age
- Baseline BMI
- Diabetes duration, insulin use, HbA1c
- Procedure type
- Eating behavior
- Depression/anxiety
- Sleep
- Medications

Diabetes as a Precision-Surgery Example

Individualized Metabolic Surgery (IMS) Score



Individualized Metabolic Surgery Score: Procedure Selection Based on Diabetes Severity


Ali Aminian, MD, Stacy A. Brethauer, MD,* Amin Andalib, MD, MSc,† Amy S. Nowacki, PhD,‡
Amanda Jimenez, MD, PhD,§ Ricard Corcelles, MD, PhD,§ Zubaidah Nor Hanipah, MD,*¶
Suriya Punchai, MD,*|| Deepak L. Bhatt, MD, MPH,** Sangeeta R. Kashyap, MD,††
Bartolome Burguera, MD, PhD,*†† Antonio M. Lacy, MD, PhD,§ Josep Vidal, MD, PhD,§††
and Philip R. Schauer, MD**

<http://riskcalc.org>



BariatricCalc





Remission after RYGB vs. SG
(Model Generating Data)

92% vs. 74%

60% vs. 25%

12% vs. 12%

Remission after RYGB vs. SG
(Validation Data)

91% vs. 91%

70% vs. 56%

8% vs. 3%

**Recommendation
in Average Risk Patients**

RYGB is suggested.

Both procedures are highly effective.

RYGB is recommended.


SG is less effective.

SG is suggested.


Both procedures are less effective.

Individualized Metabolic Surgery (IMS) Score:

Bariatric Procedure Selection Based on Diabetes Severity



BariatricCalc



Available on the
App Store

Get it on
Google play

ANNALS OF **SURGERY**
A Monthly Review of Surgical Science Since 1885

Aminian et al. Ann Surg. 2017

Surgery Can't Fully Overcome Resistant Physiology



Genomic Predictors:

Promising but not ready for routine clinical use

- Polygenic scores show more promise than single genes.
- Single genes such as FTO and MC4R have inconsistent effects.
- Prediction is improving, but clinical utility and generalizability remain uncertain.
- Take-home: Genomics may eventually help personalize treatment, but cannot yet select the operation for an individual patient.

How to Improve Outcomes of Surgery?

- Patient selection
- Procedure selection
- Optimal surgical technique
- Postop behavioral interventions
 - Dietary
 - Physical activity
 - Sleep
 - Mental health
- Adjuvant pharmacotherapy
- 2nd bariatric surgery

Technical Aspects

- Perform good surgery!
- To the best of our scientific understanding:
 - Sleeve:
 - » Bougie size 36-40
 - » Don't leave posterior fundus
 - RYGB:
 - » Pouch should exclude funds
 - » Stoma size ~15-25 mm
 - Anastomotic procedures:
 - » Limb lengths

Future of Obesity Treatment

- Personalized therapy selection
- Genomic predictors of response
- Biomarker-guided treatment selection
- Multi-omics and AI decision support
- Tailored combination therapy (Medication +/- Surgery)

Summary

- Variable outcomes are expected in a chronic, heterogeneous disease.
- Selection, anatomy, behavior, and medical factors explain part of the variability.
- Biology and genetics may explain much of what remains.
- The future is adaptive precision obesity care: right patient, right procedure, right combination of therapies.
- **Science AND selection, followed by lifelong adaptive care.**



Thank You

@Ali_Aminian_MD